Company Overview and News
KUALA LUMPUR (July 16): The FBM KLCI paused for a breather at midday break today, tracking regional markets as China’s economic growth showed a modest slowdown.
UPBMF 7113 TPGVF BATS 4162 2291 5202 7153 2089 5014 CIMDF TGLVY 1023 3204 4588 3026 5819 MYPRY
KUALA LUMPUR (July 3): Palm oil inventory is expected to continue its downtrend for the month of June before reversing from July onwards, as production rise is expected to exceed total demand, said MIDF Amanah Investment Bank Bhd Research.
KLKBY 2445 2291
KUALA LUMPUR (June 28): The FBM KLCI pared some of its losses at the midday break today amid some feeble window-dressing activities ahead of the final trading day of the first half of 2018 tomorrow.
HLFBF 7172 7052 PBLOF 7251 MLYNF 7113 BATS TPGVF 4162 1295 2089 9334 5347 3867 TNABY 2836 PNAGF MLYBY UPBMF 1082 2291 6033 TGLVY 1155 PNADF TNABF 3719
KUALA LUMPUR (June 21): Kuala Lumpur Kepong Bhd (KLK), PPB Group Bhd and Genting Plantations Bhd were among the plantation heavyweights that saw a rebound in today's trade after a decline seen in recent trading weeks.
KLKBY 2445 4065 2291
KUALA LUMPUR (June 21): The FBM KLCI fell 1.08% at the midday break today, dragged by losses at index-linked telecommunications and banking stocks.
HLFBF PBLOF 4065 1082 BATS 4162 2291 AMMHF 7765 1295 7077 KLKBY 2445 1015 4863 5347 TNABY 6888 5819 AXXTF MYTEF TNABF GEBHF 3719
KUALA LUMPUR, June 19 — The Employees’ Provident Fund (EPF) has witnessed its investment value in 10 public-listed companies (PLCs) drop by 12 per cent or RM6.09 billion, a month after the election that saw the fall of the incumbent Barisan Nasional (BN) government.
2852 1023 4863 5347 6888 TNABY 2291 AXXTF MYTEF TNABF CIMDF
KUALA LUMPUR (June 18): The FBM KLCI pared some of its losses at the midday break and was down 0.78%, with tepid sentiment tracking losses at the regional markets.
APEXF 7251 7090 7113 BATS TPGVF 4162 3034 KLKBY 5226 5347 3301 TNABY AXXTF HRGHY 5681 2291 1163 5168 TGLVY 2445 1996 6888 5819 TNABF
KUALA LUMPUR (June 18): The FBM KLCI fell 1.07% at mid-morning today as regional markets spooked by the escalating US-China trade spat mostly retreated.
PBLOF 7251 5183 PECGF 7060 UPBMF 4065 5681 2291 1163 1295 2089 5014 KLKBY 2445 5347 3301 1996 TNABY 5819 MYPRY TNABF GEBHF
KUALA LUMPUR (June 14): The FBM KLCI fell 0.94% in early trade this morning tracking losses at regional markets, dragged by key index-linked plantation stocks and blue chips.
PBLOF 4065 2291 1295 5014 6033 KLKBY 2445 PNADF 6888 5819 MYPRY AXXTF PNAGF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...